Analysts’ Top Healthcare Picks: APHB, KPTI

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ampliphi Biosciences (AMEX: APHB) and Karyopharm Therapeutics (NASDAQ: KPTI) with bullish sentiments.

Ampliphi Biosciences (AMEX: APHB)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $5. The company’s shares closed yesterday at $0.86, close to its 52-week low of $0.67.

According to, Pantginis is ranked 0 out of 5 stars with an average return of -18.7% and a 28.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.

Karyopharm Therapeutics (NASDAQ: KPTI)

H.C. Wainwright analyst Edward White assigned a Buy rating to Karyopharm Therapeutics (NASDAQ: KPTI) today. The company’s shares closed yesterday at $10.54.

According to, White is a 5-star analyst with an average return of 15.8% and a 46.6% success rate. White covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Syndax Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $17, representing a 61.3% upside.

In a report issued on November 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $18 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.